Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02358538 · ClinicalTrials.gov registry record · Phase 2
Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies
A Phase 2 study of Epilepsy, sponsored by Marinus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 10
- Study locations
NCT02358538 is a Phase 2 study of Epilepsy that has completed, run by Marinus Pharmaceuticals. The registered enrollment target is 30 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT02358538, a Phase 2 study of Epilepsy, has completed, sponsored by Marinus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 10
- Study locations
Study Summary
To evaluate the efficacy of open-label ganaxolone as adjunctive therapy for uncontrolled seizures in female children with PCDH19 mutation and other rare genetic epilepsies in an open-label proof-of-concept study.
Conditions Studied
Interventions
- DRUG Ganaxolone
Study Locations (10)
California
- Sutter Institute for Medical Research - Sacramento
- University of California San Francisco - San Francisco
New Jersey
- Northeast Regional Epilepsy Group - Hackensack
- Institute of Neurology and Neurosurgery at St. Barnabas - Livingston
Arizona
- Phoenix Children's Hospital - Phoenix
Georgia
- Center for Rare Neurological Diseases - Norcross
Indiana
- JWM Neurology - Indianapolis
Massachusetts
- Boston Children's Hospital - Boston
Ohio
- Nationwide Children's Hospital - Columbus
Other
- Bambino Gesu Children's Hospital, IRCCS - Rome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-11-06 |
| Est. Completion | 2019-01-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02358538
The ClinicalTrials.gov registry entry for NCT02358538 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The listed sponsor is Marinus Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Ganaxolone is the first listed.
NCT02358538 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, New Jersey, Arizona.
Frequently Asked Questions
What is clinical trial NCT02358538 about?
NCT02358538 is a clinical study titled "Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies". To evaluate the efficacy of open-label ganaxolone as adjunctive therapy for uncontrolled seizures in female children with PCDH19 mutation and other rare genetic epilepsies in an open-label proof-of-concept study.
What is the current status of trial NCT02358538?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2015-11-06. Estimated completion is 2019-01-04.
What conditions does trial NCT02358538 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT02358538?
The interventions under investigation include: Ganaxolone (DRUG).
Who is sponsoring clinical trial NCT02358538?
This trial is sponsored by Marinus Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02358538 being conducted?
This trial has 10 study locations across Arizona, California, Georgia, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.